EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Systemic Bevacizumab Therapy in Recurrent Respiratory Papillomatosis: First Preliminary Study From Azerbaijan

Ramil Hashimli iD, Aynur Aliyeva iD

Laryngoscope Investigative Otolaryngology · 2026-04 · 11 (2)

DOI: 10.1002/lio2.70395 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Laryngoscope Investigative Otolaryngology, online erschienen am 07.04.2026. Verfasst von Ramil Hashimli und 1 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine and Health Sciences Karabakh University Khankendi Azerbaijan. Die Arbeit nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To report the first clinical experience from Azerbaijan using systemic bevacizumab therapy for the treatment of recurrent respiratory papillomatosis (RRP) and to evaluate its efficacy in reducing recurrence and surgical burden in both pediatric and adult patients.

Methods

A retrospective case series of five patients (four pediatric, one adult) with confirmed RRP treated at a single institution. All patients had a history of multiple surgical interventions and were considered candidates for adjuvant systemic therapy. A single intravenous dose of bevacizumab (5–10 mg/kg) was administered, and patients were followed clinically and endoscopically to assess remission duration and recurrence.

Results

All patients achieved prolonged remission following a single intravenous dose of bevacizumab. Pediatric patients experienced remission periods ranging from 8 to 24 months, with one child remaining recurrence‐free for over 2 years. The adult patient, with severe tracheobronchial involvement and a history of 112 surgeries, achieved a 6‐month remission—the longest interval between interventions in over a decade. No adverse drug‐related events were reported. In this small series, a single bevacizumab dose was associated with prolonged remission intervals; however, these findings should be interpreted cautiously and viewed as hypothesis‐generating.

Conclusion

Systemic bevacizumab may be a promising adjuvant option for selected patients with severe RRP, as it was associated with longer interventional‐free intervals in this retrospective patient series. Definitive conclusions regarding efficacy and surgical burden reduction require prospective studies with standardized severity measures and comparator groups. This first reported clinical experience from Azerbaijan contributes valuable real‐world data to the emerging global evidence base supporting anti‐VEGF therapy in RRP. Larger prospective studies are needed to establish optimal dosing regimens and long‐term outcomes.

Schlagwörter

Stichwörter der Autor:innen

Azerbaijanairway papillomaanti‐VEGF therapypediatric RRPrecurrent respiratory papillomatosissystemic bevacizumab

Autor:innen und Institutionen

  • Faculty of Medicine and Health Sciences Karabakh University Khankendi Azerbaijan.
  • Department of Surgery Denver Health Medical Center Denver Colorado USA.
  • Neuroscience Doctoral Program Yeditepe University Istanbul Turkey.

ORCID-Profile: Ramil Hashimli, Aynur Aliyeva

Zitieren

APA

Hashimli, R., & Aliyeva, A. (2026). Systemic Bevacizumab Therapy in Recurrent Respiratory Papillomatosis: First Preliminary Study From Azerbaijan. Laryngoscope Investigative Otolaryngology, 11(2). https://doi.org/10.1002/lio2.70395

Vancouver

Hashimli R, Aliyeva A. Systemic Bevacizumab Therapy in Recurrent Respiratory Papillomatosis: First Preliminary Study From Azerbaijan. Laryngoscope Investigative Otolaryngology. 2026;11(2). doi:10.1002/lio2.70395

BibTeX
@article{Hashimli2026,
  author = {Hashimli, Ramil and Aliyeva, Aynur},
  title = {Systemic Bevacizumab Therapy in Recurrent Respiratory Papillomatosis: First Preliminary Study From Azerbaijan},
  journal = {Laryngoscope Investigative Otolaryngology},
  year = {2026},
  volume = {11},
  number = {2},
  doi = {10.1002/lio2.70395}
}
Kostenlos starten →